The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement

Journal of Immunology

Volumn 165, Issue 6, 2000, Pages 3111-3118

  Di Carlo, E ^a   Comes, A ^a   Basso, S ^a   De Ambrosis, A ^a   Meazza, R ^a   Musiani, P ^a   Moelling, K ^a   Albini, A ^a   Ferrini, S ^a  

^a CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; EFFECTOR CELL; GENE THERAPY; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; XENOGRAFT;

EID: 0034665093     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.6.3111     Document Type: Article

References (56)

1. Cancer tumor antigens
2. Cancer vaccines
3. CTL-defined cancer vaccines: Perspectives for active immunotherapeutic interventions in minimal residual disease
4. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
5. TAP off - Tumors on
6. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines
7. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
8. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer
9. β2-Microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation
10. Identification of human cancers deficient in antigen processing
11. IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer
12. Natural killer cells and tumor therapy
13. Reversal of natural killing susceptibility in target cells expressing transfected class I genes
14. Recognition of major histocompatibility complex class I antigens by natural killer cells
15. Major histocompatibillty complex class I-specific receptors on human natural killer and T lymphocytes
16. Killer cell inhibitory receptors diversity, specificity and function
17. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor
18. The multifaceted regulation of interleukin- 15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens
19. + hematopoietic progenitor cells
20. Interleukin (IL)15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor
21. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism
22. IL-15 is chemotactic for natural killer cells and stimulates their adhesion to vascular endothelium
23. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells
24. Studies evaluating the anti-tumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2
25. Is IL-15 a suitable candidate for cancer gene therapy?
26. Immunogene therapy for murine fibrosarcoma using IL-15 gene with high translational efficiency
27. Dissimilar anti-tumor reactions induced by tumor cells engineered with interleukin-2 or interleukin-15 gene in nude mice
28. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection
29. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
30. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12
31. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12
32. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response
33. Subtherapeutic doses of interleukin-15 augment the anti-tumor effect of interleukin-12 in a B16F10 melanoma model in mice
34. Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion, role of different signal peptides
35. Long-lasting anti-metastic efficiency of IL-12-encoding plasmid DNA
36. 15(N)nitrate in biological fluids
37. Evaluation of tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing
38. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines
39. Differential intracellular trafficking, secretion and endosomal localization of two IL-15 isoforms
40. The regulation and biological activity of interleukin 12
41. Regulation of murine macrophage IL-12 receptor 2β1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells
42. Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8
43. Generation of nitric oxide by human neutrophils
44. Copurification of 130 kD nitric oxide synthase and a 22 kD link from human neutrophils
45. Synthesis of nitric oxide from L-arginine: A recently discovered pathway induced by cytokines with antitumor and antimicrobial activity
46. Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells
47. Granulocyte colony stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo: Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells
48. Neutrophil-mediated damage to human vascular endothelium
49. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-α, IFN-γ and TNF-α
50. Mechanisms of neutrophil-induced parenchymal cell injury
51. 2+ and tyrosine signaling pathways in human neutrophils
52. Interleukin-15 (IL-15) induces NF-κB activation and IL-8 production in human neutrophils
53. IL-12 induces IFN-γ expression and secretion in mouse peritoneal macrophages
54. + lymphoid dendritic cells
55. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon-γ
56. Cytokines, tumor cell death and immunogenicity: A question of choice